Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy ... the US for diabetes ...

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented One presentation will summarize results from the ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

So how does tirzepatide work and differ from Ozempic? And with a price tag of $315–$645 per month for the starting dose, why is it ... acts on one (GLP-1). This dual action is thought to be ...

In humans, nasal foralumab modulates immune responses by inducing regulatory-type T cells. Semaglutide is an effective ...

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...

Tirzepatide is a dual GIP and GLP-1 receptor agonist ... Last month, Lilly launched a discounted single-dose vial version of ...